The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

The outbreak of SARS-CoV-2, the cause of COVID-19, is ongoing. New and effective antiviral agents that combat the disease are needed urgently. Here, we found that an inhaled corticosteroid, ciclesonide, suppresses the replication of coronaviruses, including betacoronaviruses (murine hepatitis virus type 2 [MHV-2], MERS-CoV, SARS-CoV, and SARS-CoV-2) and an alphacoronavirus (human coronavirus 229E [HCoV-229E]), in cultured cells. Ciclesonide is safe; indeed, it can be administered to infants at high concentrations. Thus, ciclesonide is expected to be a broad-spectrum antiviral drug that is effective against many members of the coronavirus family. It could be prescribed for the treatment of MERS and COVID-19.

Article activity feed

  1. SciScore for 10.1101/2020.08.22.258459: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The cells were then incubated with a mixture of rabbit anti-SARS-nsp4 (1:500; ab181620; Abcam, USA) and mouse anti-dsRNA (1:1000; J2-1709; Scicons, Hungary) antibodies for 1 h at RT, washed three times with PBS, and incubated for 1 h at RT with a mixture of Alexa Fluor 594 conjugated anti-rabbit IgG (1:500; A11012; ThermoFisher, USA) and Alexa Fluor 488-conjugated anti-mouse IgG (1:500; A10680; ThermoFisher, USA).
    anti-SARS-nsp4
    suggested: None
    anti-dsRNA
    suggested: (Millipore Cat# MABE1134, RRID:AB_2819101)
    anti-rabbit IgG
    suggested: (Molecular Probes Cat# A-11012, RRID:AB_141359)
    anti-mouse IgG
    suggested: (Thermo Fisher Scientific Cat# A-10680, RRID:AB_2534062)
    Experimental Models: Cell Lines
    SentencesResources
    Cells and viruses: Hep-2, HeLa229, MDCK, Calu-3, Vero, Vero/TMPRSS2 and VeroE6/TMPRSS2 cells were maintained in Dulbecco’s modified Eagle medium high glucose (DMEM, Sigma-Aldrich, USA), and DBT cells were maintained in DMEM (Nissui, Japan), supplemented with 5% fetal bovine serum (Gibco-BRL, USA).
    Hep-2
    suggested: None
    MDCK
    suggested: CLS Cat# 602280/p823_MDCK_(NBL-2, RRID:CVCL_0422)
    Vero
    suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
    VeroE6/TMPRSS2
    suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
    BHK-21 cells were grown in a single well of a six-well plate in 10% FCS-MEM and transfected with 3 μg of BAC plasmid with Lipofectamine 3,000 (Thermo Fisher, USA)
    BHK-21
    suggested: None
    The supernatants were collected and propagated once using Vero/TMPRSS2 cells.
    Vero/TMPRSS2
    suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)
    Vero and VeroE6/TMPSS2 cells were used to passage MERS-CoV and SARS-CoV-2, respectively.
    VeroE6/TMPSS2
    suggested: None
    Software and Algorithms
    SentencesResources
    Indexed libraries were then converted and sequenced (150-bp paired-end reads) using the DNBSEQ-G400 (MGI Tech., Shenzhen, China; operated by GENEWIZ, South Plainfield, NJ, USA).
    GENEWIZ
    suggested: (GENEWIZ, RRID:SCR_003177)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.